查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1491689

導管相關血流感染市場：按藥物類別、給藥途徑、適應症、分銷管道分類 - 全球預測 2024-2030 年

Catheter-related Bloodstream Infections Market by Drug Class (Cefazoline, Ceftazidime, Cloxacillin), Route of Administration (Injectable, Oral), Indication, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

導管相關血流感染市場規模預計2023年為16.4億美元，預計2024年將達到17.4億美元，2030年將達到24.6億美元，複合年成長率為5.88%。

導管相關性血流感染 (CRBSI) 是細菌或真菌經由中心靜脈管或導管進入血流時發生的感染疾病，中心靜脈管或導管是放置在大靜脈中進行治療的管子。醫院和臨床環境中接受靜脈注射治療的患者數量不斷增加，對旨在降低 CRBSI 發生率的先進導管的需求顯著增加。此類感染疾病在全球日益流行，凸顯了對確保靜脈注射藥物安全輸送的產品的需求，從而推動了市場成長。然而，嚴格的藥品監管和產品召回是主要企業面臨的重大挑戰。此外，我們還看到專門從事醫療設備和醫院護理解決方案的主要公司之間聯盟和合併的重大趨勢。這些合作旨在創新和增強導管技術以預防感染，從而擴大分銷網路並改善產品供應，從而提高市場覆蓋率和滲透率。

主要市場統計
基準年[2023] 16.4億美元
預測年份 [2024] 17.4億美元
預測年份 [2030] 24.6億美元
複合年成長率（%） 5.88%

區域洞察

由於醫療保健系統結構和政策的多樣性，美洲地區的消費者需求和購買行為有所不同，尤其是美國和加拿大。美國醫療技術採用率很高，包括先進的 CRBSI 預防技術，如抗菌導管和洛赫西定敷料。已分配大量資金用於 CRBSI 的研究，從而導致持續的臨床試驗和感染預防的發展。疾病管制與預防美國(CDC) 在製定指引和方案方面也發揮著至關重要的作用。同時，EMEA（歐洲、中東和非洲）地區對 CRBSI 的反應呈現多樣化，反映出醫療基礎架構層、資金和公共衛生政策的差異。歐盟國家受益於合作醫療標準和通用研究舉措。正在進行的研究重點是 CRBSI 預防的技術和程序方面。歐盟委員會的框架支持成員國之間開展聯合研究來解決 HAI。此外，在亞太地區，中國、日本和印度等國家是醫療保健領域的主要參與者，並深受 Theme_KEYWORD (CRBSI) 的影響。由於人口密度高和醫療基礎設施不穩定，這些感染疾病在該地區尤其嚴重。最近關於 CRBSI 預防技術的區域專利強調了導管設計和抗菌應用的改進。對醫療保健改善的投資，包括政府主導的感染控制通訊協定，是穩健的。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在導管相關血流感染市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對導管相關血流感染市場供應商的現況進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在導管相關血流感染市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對靜脈細菌感染疾病的日益關注以及對有效治療方法的需求
      • 提高對導管相關血流的認知宣傳活動
    • 抑制因素
      • 有關藥品核准和產品召回的嚴格政府法規
    • 機會
      • 首選政府針對細菌感染疾病的措施和政策
      • 持續進行研究和開發活動，以推動藥物輸送和開發新藥的進步
    • 任務
      • 導管相關的血流感染過敏原和與藥物相關的嚴重健康問題
  • 市場區隔分析
    • 藥物類別：廣泛使用Cefazolin和氯唑西林藥物治療導管引起的細菌感染疾病
    • 適應症：人們對有效管理以及預防和治療病毒和寄生蟲感染疾病的興趣日益濃厚
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章依藥物類別分類的導管相關血流感染市場

  • Cefazolin
  • 頭孢他茲健身房
  • 氯唑西林
  • Daptomycin
  • Echinocandins
  • Teicoplanin
  • 萬古黴素

第7章導管相關血流感染市場：依給藥途徑

  • 可注射的
  • 口服

第8章導管相關血流感染市場（按適應症）

  • 細菌感染疾病
  • 黴菌感染疾病
  • 病毒和寄生蟲感染疾病

第9章導管相關血流感染市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲導管相關血流感染市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區導管相關血流感染市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲導管相關血流感染市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Citius Pharmaceuticals 宣布完成 Mino-Lok 用於緩解感染導管的 3 期研究的招募
    • BD 與 Bactiguard 合作，增強全球感染預防Foley導管的可及性
    • FDA核准DefenCath 是預防血液透析機病人導管相關血流感染的重要一步。
  • 戰略分析和建議

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5D693B46C67B

[187 Pages Report] The Catheter-related Bloodstream Infections Market size was estimated at USD 1.64 billion in 2023 and expected to reach USD 1.74 billion in 2024, at a CAGR 5.88% to reach USD 2.46 billion by 2030.

Catheter-related bloodstream infections (CRBSIs) refer to infections acquired when bacteria and fungi enter the bloodstream through a central line or catheter, which are tubes placed in large veins for medical treatments. Increased patient admissions in hospitals and clinical settings that utilize intravenous treatments have significantly boosted the demand for advanced catheters designed to reduce the incidence of catheter-related bloodstream infections (CRBSIs). The rising prevalence of these infections globally underscores the need for products that guarantee safer delivery of intravenous medicines, thus propelling market growth. However, strict regulations related to drugs and product recalls are the significant challenge faced by the key companies. Moreover, there is a notable trend of partnerships and amalgamations among significant companies that specialize in medical devices and hospital care solutions. These collaborations aim to innovate and enhance catheter technologies that prevent infections, resulting in expanded distribution networks and improved product offerings, which in turn enhance market reach and penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 1.64 billion
Estimated Year [2024] USD 1.74 billion
Forecast Year [2030] USD 2.46 billion
CAGR (%) 5.88%

Regional Insights

The Americas, particularly the United States and Canada show differing degrees of consumer needs and purchasing behaviors due to diversity in healthcare system structures and policies. The United States has a significant rate of medical technology adoption, which includes advanced CRBSI prevention technologies like antimicrobial catheters and chlorhexidine dressings. Substantial funding is being allocated to research on CRBSIs, which will lead to ongoing clinical trials and developments in infection prevention. The Centers for Disease Control and Prevention (CDC) also plays a pivotal role in setting guidelines and protocols. At the same time, the EMEA region shows varied responses to CRBSIs, reflecting different healthcare infrastructure levels, funding, and public health policies. Countries within the EU benefit from cooperative healthcare standards and shared research initiatives. Ongoing research focuses on the technological and procedural aspects of CRBSI prevention. European Commission frameworks support research collaborations across member states to address HAIs. Moreover, in the Asia Pacific region, countries including China, Japan, and India are key players in the healthcare sector, profoundly impacted by catheter-related bloodstream infections (CRBSIs). These infections are especially critical due to the region's high population densities and varying healthcare infrastructure. Recent regional patents for CRBSI prevention technology emphasize improvements in catheter design and antimicrobial applications. Investments are robust in healthcare improvements, including infection control protocols driven by the government.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Catheter-related Bloodstream Infections Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing concerns about intravenous bacterial infections and the need for effective treatment options
      • Growing number of educational campaigns for awareness of catheter-related bloodstream
    • Market Restraints
      • Strict government regulations related to drug approvals and cases of product recalls
    • Market Opportunities
      • Favorable government initiatives and policies for bacterial infectious diseases
      • Advancements in the drug delivery and ongoing R&D activities for the novel drug development
    • Market Challenges
      • Allergens and significant health concerns associated with catheter-related bloodstream infections medications
  • Market Segmentation Analysis
    • Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
    • Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Catheter-related Bloodstream Infections Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Catheter-related Bloodstream Infections Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters

Citius Pharmaceuticals completed patient enrollment for the pivotal Phase 3 clinical trial of Mino-Lok, an antibiotic therapy designed to treat catheter-related bloodstream infections (CRBSIs). This significant milestone marks a crucial step towards providing a potentially life-saving treatment option to salvage infected central venous catheters (CVCs), thereby avoiding the need for their removal and replacement. This therapeutic approach aims to enhance patient outcomes and seeks to reduce healthcare costs and procedural complications associated with the current standard practice of catheter replacement. [Published On: 2024-01-02]

BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters

Becton Dickinson and Company (BD) has secured an exclusive global licensing partnership, excluding China, with Bactiguard for its innovative Bactiguard-coated Foley catheters. This agreement marks a significant expansion in the distribution of Bactiguard's infection prevention technology, which is integrated into Foley catheters to reduce the risk of catheter-related bloodstream infections. This partnership aims to enhance patient outcomes by broadening the availability of these advanced medical devices, potentially impacting healthcare standards globally. [Published On: 2023-12-14]

FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients

CorMedix Inc. received U.S. Food and Drug Administration (FDA) approval for DefenCath, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients. This approval underscores the effectiveness of DefenCath in reducing the risks of CRBSIs, a common and serious complication that affects patients with central venous catheters. DefenCath's active ingredient is taurolidine, which is known for its antimicrobial properties and significantly enhances patient safety during hemodialysis. [Published On: 2023-11-15]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Catheter-related Bloodstream Infections Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Catheter-related Bloodstream Infections Market, highlighting leading vendors and their innovative profiles. These include Advacare Pharma, AstraZeneca PLC, Bactiguard AB, Becton, Dickinson and Company, CorMedix Inc, Fresenius Medical Care AG, Glenmark Pharmaceuticals Ltd., IntegraDose Compounding Services, LLC, Johnson & Johnson Services, Inc, JoinHub Pharma, Lupin Ltd., Lyka Hetero Healthcare Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Catheter-related Bloodstream Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cefazoline
    • Ceftazidime
    • Cloxacillin
    • Daptomycin
    • Echinocandin
    • Teicoplanin
    • Vancomycin
  • Route of Administration
    • Injectable
    • Oral
  • Indication
    • Bacterial Infections
    • Fungal Infection
    • Viral & Parasitic Infections
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing concerns about intravenous bacterial infections and the need for effective treatment options
      • 5.1.1.2. Growing number of educational campaigns for awareness of catheter-related bloodstream
    • 5.1.2. Restraints
      • 5.1.2.1. Strict government regulations related to drug approvals and cases of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives and policies for bacterial infectious diseases
      • 5.1.3.2. Advancements in the drug delivery and ongoing R&D activities for the novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Allergens and significant health concerns associated with catheter-related bloodstream infections medications
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
    • 5.2.2. Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Catheter-related Bloodstream Infections Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cefazoline
  • 6.3. Ceftazidime
  • 6.4. Cloxacillin
  • 6.5. Daptomycin
  • 6.6. Echinocandin
  • 6.7. Teicoplanin
  • 6.8. Vancomycin

7. Catheter-related Bloodstream Infections Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Catheter-related Bloodstream Infections Market, by Indication

  • 8.1. Introduction
  • 8.2. Bacterial Infections
  • 8.3. Fungal Infection
  • 8.4. Viral & Parasitic Infections

9. Catheter-related Bloodstream Infections Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Catheter-related Bloodstream Infections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Catheter-related Bloodstream Infections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Catheter-related Bloodstream Infections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters
    • 13.3.2. BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters
    • 13.3.3. FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET RESEARCH PROCESS
  • FIGURE 2. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA CATHETER-RELATED BLOODSTREAM INFE